. . "approved"@en . "Halomonth"@en . . "Pimozida"@en . . " "@en . . . . . "Humans and other mammals"@en . . . . "Take without regard to meals."@en . . . . "Used for the suppression of motor and phonic tics in patients with Tourette's Disorder who have failed to respond satisfactorily to standard treatment."@en . . . . . . . "Grapefruit and grapefruit juice should be avoided throughout treatment. Grapefruit can increase serum levels of this product."@en . . . "Neoperidole"@en . "Pimozide"@en . "Greater than 50% absorption after oral administration. Serum peak appears 6-8 hours post ingestion."@en . "The ability of pimozide to suppress motor and phonic tics in Tourette's Disorder is thought to be primarily a function of its dopaminergic blocking activity. Pimozide binds and inhibits the dopamine D2 receptor in the CNS. "@en . . . . . . . "2062-78-4"@en . . . . . "A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403)"@en . . . . . . . . . . "Pimozidum"@en . . . . . . . "Opiran"@en . . . . . . "29 ± 10 hours (single-dose study of healthy volunteers)."@en . . . . . . . "Pimozide"@en . . "Orap"@en . . "LD₅₀ = 1100 mg/kg (rat, oral), 228 mg/kg (mouse, oral)"@en .